cognitive cybersecurity intelligence

News and Analysis


Point Bio Prostate Cancer Therapy Meets Phase 3 Goal, But Results Still Disappoint

Point Biopharma’s radiopharmaceutical prostate cancer therapy, PNT2002, reached its main goal in a clinical trial, yet questions were raised about its effectiveness against a similar Novartis drug. The Point therapy showed a 29% reduction in the risk of radiographic progression or death compared to control drugs, but was less effective than expected, potentially impacting the commercial viability of PNT2002. Point and partner Lantheus plan to report further data next year.

Source: –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts